ライブ

FierceBiotechExelixis’ Cabometyx successor fails primary endpoint in colorectal cancer trial amid FDA review Clinical OMICsGene Therapy Restores Brain Function and Behavior in Fragile X Syndrome Clinical OMICsSleep Habits Can Influence Effects of Alzheimer’s Disease Risk Genes Endpoints NewsHHS launches broad effort to expand and speed up clinical trials Clinical OMICsMagnetic Algae Microrobots Boost Chemotherapy Penetration in Bladder Tumors Thermo FisherThermo Fisher Expands HLA-DQ Coverage in LABScreen ExPlex Transplant Antibody Panel - Lab Manager Thermo FisherAlejandra Bailon Takes on Expanded Leadership Role as Vice President, Human Resources for Thermo Fisher Scientific’s Chromatography and Mass Spectrometry Division - hrtoday.in FierceBiotechFederal health agencies unveil plan to speed up phase 1 clinical trials by 6 to 12 months BioWorldSCOTUS considers PhRMA challenge to trade secret disclosures BioWorldEurope’s health system under threat; prevention and innovation key BioWorldBionyra closes $165M series A to develop antibodies for inflammation BioWorldCynata’s Cymerus flops in osteoarthritis, GVHD

BioWorld 2026年6月22日

Bionyra closes $165M series A to develop antibodies for inflammation

Bionyra Pharma has emerged with a $165 million oversubscribed series A and a portfolio of three antibodies with extended half-lives that are designed to offer i...

Bionyra Pharma has emerged with a $165 million oversubscribed series A and a portfolio of three antibodies with extended half-lives that are designed to offer improvements over existing classes of monoclonal antibodies for treating chronic inflammatory diseases.